| 2021 EFPIA DISCLOSURE (inc. Vaccines Europe) Date of publication: 21/06/2022 | | | | | | | | | | | | |
|--|--|---|-----------------------|---|---------------------|--|--|---|---------------------------|---------------------------------|---|------------|
| | Full Name | HCPs: City of Principal Practice HCOs: city where registered HCOs: Country of Principal Practice Principal Practice Address Principal Practice Address Principal Practice Address OPTIONAL | | | | | Contribution to costs of Events | | | Fee for service and consultancy | | 21/00/2022 |
| | | | | | | Donations and Grants to HCOs and POs | Sponsorship agreements with HCOs POs / third parties appointed by HCOs to manage an Event | Registration Fees | Travel & Accommodation | Fees | Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract | |
| | INDIVIDUAL NAMED DISCLOSURE | E - one line per HCP (i. | i.e. all transfers of | value during a year for an individual H | CP will be summed t | up: itemization sho | uld be available for | the individual Reci | pient or public auth | orities' consultatio | n only, as appropria | te) |
| | | | | | | N/A | N/A | | | | | |
| PS | OTHER, NOT INCLUDED ABOVE - where information cannot be diclsoed on an individual basis for legal reasons | | | | | | | | | | | |
| HCPs | Aggregate amount attributable to transfers of value to such Recipients | | | | | | N/A | | | | | |
| | Number of Recipients in aggregate disclosure | | | | | | N/A | | | | | |
| | % of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed | | | | | | N/A | | | | | |
| INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate | | | | | | | | | | | | fal |
| | Coalition for life-Course Immunisation | | | | | | l dia be available joi | l I I I I I I I I I I I I I I I I I I I | orent or public dutil | ortics consultatio | ii oiliy, us uppropriul | |
| | European Diabetes Forum | | | | | | | | | | | |
| | European Nurses Organisation European Nurses Organisation | | | | | | | | | | | |
| S | International Diabetes Federation | | | | | | | | | | | |
| HCOs | University of Antwerpen | | | | | | | | | | | |
| | OTHER, NOT INCLUDED ABOVE - where information cannot be a | | | | | | ividual basis for leg | al reasons | | | | |
| | Aggregate amount attributable to transfers of value to such Recipients | | | | | | N/A | | | | | |
| | Number of Recipients in aggregate disclosure | | | | | | N/A | | | | | |
| | % of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed | | | | | | N/A | | | | | |
| | | Т | | ation of the transfer of value | | 1 | | | | | | |
| | Name | | | | | to the state of | | | | | | |
| | INDIVIDUAL NAMED DISCLOSURE - one line per PO (i.e. all transfers of value during a year for an individual PO will be summed up European Patient Forum Grant to support the data saves lifes initiative | | | | | | a be available for t | ne Individual Recipi | ent or public author | rities' consultation | only, as appropriate |) |
| | European Patient Forum European Patient Forum | Grant to support the data saves lifes initiative Grant to support the Euroepan Patients' Forum's 2021 Congress | | | | | | | | | | |
| | SYNERGIST | Support for the Patient Engagement Open Forum 2021 | | | | | 10.000 | | | | | |
| | Manufaktur fur Antworten | | | | | | | | | 300 | | |
| | Axial Spondyloarthritis International Federation Connecting healthcare award | | | | | | | | | 500 | | |
| ő | Asociación Española de Afectados por Linfoma, Mieloma y Leucemia | | | | | | | | | | | |
| 2 | Global Alliance of Mental Illness Advocacy Networks - Europe | Connecting nearthcare award | | | | | | | | | | |
| | ga Reumatiker Connecting healthcare award OTHER, NOT INCLUDED ABOVE - where information cannot be a | | | | | | l | l | | | | |
| | | diclsoed on an ind N/A | | al reasons | | | | | | | | |
| | Aggregate amount attributable to transfers of value to such Recipients Number of Recipients in aggregate disclosure | | | | | | N/A | | | | 1 | |
| | % of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed | | | | | | N/A N/A | | | | | |
| | | | | | | | | | | | | |
| R&D | AGGREGATE DISCLOSURE | | | | | | | | | | | |
| R8 | Transfers of Value re Research & Development as defined N/A | | | | | | | | | | | |